AFTX-201 uses a proprietary capsid to deliver a human BAG3 transgene, aiming to restore cardiac function with lower doses than conventional gene therapies.

HealthDay News — Among young adults, first ST-segment elevation myocardial infarction (STEMI) in-hospital mortality increased from 2011 to 2022, according to a study published online February 26 in ...

HealthDay News — Microplastics have been found in most prostate tumors, according to a small study presented at the American Society of Clinical Oncology annual Genitourinary Cancers Symposium, held ...

No significant improvement seen in overall survival with addition of hormone therapy to post-radical prostatectomy radiotherapy.

HealthDay News — Daily aspirin use does not offer a reliable way to prevent colorectal cancer (CRC), according to a review published online February 26 in the Cochrane Database of Systematic Reviews.

HealthDay News — A growing number of states are rolling back financial help for HIV medications. An analysis released March 2 by the health research group KFF found that 18 states have adopted ...

Lomitapide is a microsomal triglyceride transfer protein inhibitor designed to inhibit the formation of chylomicrons and very low-density lipoprotein.

In the phase 3 VERIFY trial, rusfertide was associated with a significantly higher proportion of patients achieving clinical response compared with placebo.

The FDA grants Priority Review to brepocitinib for dermatomyositis after trial results show significant muscle and skin improvements in patients.

Nipocalimab, an FcRn blocker, receives FDA Fast Track status for SLE treatment after demonstrating significant improvements in disease activity.

This once-weekly C-type natriuretic peptide analog functions by antagonizing overactive FGFR3 signaling to improve growth in pediatric patients.

Treatment with fenebrutinib significantly reduced the annualized relapse rate by 51% compared with teriflunomide. Topline data were announced from a second phase 3 trial evaluating fenebrutinib, an ...